Contact Information
A Multicenter, Randomized, Double Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy M16 067
Gender
Any
Age Group
Any